Stock Analysis on Net
Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Common Stock Valuation Ratios (Price Multiples) 
Quarterly Data

Microsoft Excel

Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).

Historical Valuation Ratios (Summary)

Boston Scientific Corp., historical price multiples (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Price to earnings (P/E) 88.37 105.44 99.47 71.20 79.58 63.31 55.06 121.00 304.26 — 13.68 13.56 11.72 11.86 51.90 42.77 28.42 33.06 — — —
Price to operating profit (P/OP) 43.04 41.05 41.68 40.54 46.40 52.01 56.65 133.43 424.69 — 630.22 80.81 44.72 36.71 34.77 36.58 31.15 36.68 — — —
Price to sales (P/S) 5.72 5.34 4.73 4.79 4.94 5.25 5.28 5.68 6.04 5.54 4.99 5.31 4.66 5.19 5.44 5.92 5.14 5.62 — — —
Price to book value (P/BV) 4.18 3.85 3.37 3.42 3.59 3.75 3.68 3.99 3.89 3.58 3.24 3.46 3.64 4.02 5.83 6.33 5.53 6.33 5.91 6.00 5.79

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Boston Scientific Corp. P/E ratio increased from Q3 2022 to Q4 2022 but then decreased significantly from Q4 2022 to Q1 2023.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Boston Scientific Corp. P/OP ratio decreased from Q3 2022 to Q4 2022 but then increased from Q4 2022 to Q1 2023 exceeding Q3 2022 level.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Boston Scientific Corp. P/S ratio increased from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Boston Scientific Corp. P/BV ratio increased from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.

Price to Earnings (P/E)

Boston Scientific Corp., historical P/E calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
No. shares of common stock outstanding1 1,437,698,101 1,434,780,104 1,432,311,282 1,431,614,313 1,429,571,199 1,426,724,712 1,424,992,477 1,423,852,648 1,420,910,855 1,417,165,707 1,431,921,459 1,430,674,668 1,399,350,122 1,396,195,349 1,393,823,592 1,392,973,426 1,390,652,506 1,385,961,926 1,383,800,781 1,382,924,777 1,379,810,502
Selected Financial Data (US$)
Net income (loss) available to common stockholders (in millions) 300 125 174 246 97 81 405 172 327 196 (169) (153) 11 3,996 126 154 424 386 432 555 298
Earnings per share (EPS)2 0.59 0.45 0.42 0.58 0.53 0.69 0.77 0.37 0.14 -0.08 2.57 2.78 3.06 3.37 0.78 1.00 1.29 1.21 0.00 0.00 0.00
Share price1, 3 51.94 47.18 41.53 41.23 42.03 43.71 42.50 44.70 43.04 38.75 35.21 37.73 35.89 39.91 40.59 42.86 36.73 39.86 35.38 33.61 29.48
Valuation Ratio
P/E ratio4 88.37 105.44 99.47 71.20 79.58 63.31 55.06 121.00 304.26 — 13.68 13.56 11.72 11.86 51.90 42.77 28.42 33.06 — — —
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 33.21 26.76 21.95 22.24 25.48 29.13 31.42 33.80 36.79 48.49 58.45 58.36 45.61 41.83 — — — — — — —
Cigna Group 11.43 13.13 14.99 15.60 15.72 13.43 8.43 8.60 10.62 8.71 14.60 12.08 13.82 13.26 — — — — — — —
CVS Health Corp. 22.61 27.53 40.34 16.30 16.49 17.39 16.78 14.94 14.44 12.88 10.69 10.20 10.94 14.15 — — — — — — —
Elevance Health Inc. 17.46 19.20 18.75 18.07 20.46 18.13 18.65 22.10 19.99 15.87 14.35 11.97 14.80 15.96 — — — — — — —
Humana Inc. 20.27 22.52 25.24 19.26 18.48 18.34 22.09 22.82 15.20 14.48 13.49 15.26 19.09 18.10 — — — — — — —
Intuitive Surgical Inc. 79.43 64.99 56.03 52.74 55.10 59.94 71.86 69.15 89.95 87.47 82.17 70.73 44.27 48.72 — — — — — — —
Medtronic PLC 22.61 23.38 29.39 30.66 46.71 46.56 55.13 42.80 32.34 26.30 25.38 31.86 32.75 28.78 — — — — — — —
UnitedHealth Group Inc. 22.01 22.46 26.13 27.70 27.29 26.03 27.92 27.41 23.06 20.54 17.70 16.88 19.91 20.48 — — — — — — —

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Data adjusted for splits and stock dividends.

2 Q1 2023 Calculation
EPS = (Net income (loss) available to common stockholdersQ1 2023 + Net income (loss) available to common stockholdersQ4 2022 + Net income (loss) available to common stockholdersQ3 2022 + Net income (loss) available to common stockholdersQ2 2022) ÷ No. shares of common stock outstanding
= (300,000,000 + 125,000,000 + 174,000,000 + 246,000,000) ÷ 1,437,698,101 = 0.59

3 Closing price as at the filing date of Boston Scientific Corp. Quarterly or Annual Report.

4 Q1 2023 Calculation
P/E ratio = Share price ÷ EPS
= 51.94 ÷ 0.59 = 88.37

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Boston Scientific Corp. P/E ratio increased from Q3 2022 to Q4 2022 but then decreased significantly from Q4 2022 to Q1 2023.

Price to Operating Profit (P/OP)

Boston Scientific Corp., historical P/OP calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
No. shares of common stock outstanding1 1,437,698,101 1,434,780,104 1,432,311,282 1,431,614,313 1,429,571,199 1,426,724,712 1,424,992,477 1,423,852,648 1,420,910,855 1,417,165,707 1,431,921,459 1,430,674,668 1,399,350,122 1,396,195,349 1,393,823,592 1,392,973,426 1,390,652,506 1,385,961,926 1,383,800,781 1,382,924,777 1,379,810,502
Selected Financial Data (US$)
Operating income (loss) (in millions) 552 402 358 423 466 180 387 262 370 50 (205) (71) 146 210 383 384 541 319 388 392 407
Operating profit per share2 1.21 1.15 1.00 1.02 0.91 0.84 0.75 0.34 0.10 -0.06 0.06 0.47 0.80 1.09 1.17 1.17 1.18 1.09 0.00 0.00 0.00
Share price1, 3 51.94 47.18 41.53 41.23 42.03 43.71 42.50 44.70 43.04 38.75 35.21 37.73 35.89 39.91 40.59 42.86 36.73 39.86 35.38 33.61 29.48
Valuation Ratio
P/OP ratio4 43.04 41.05 41.68 40.54 46.40 52.01 56.65 133.43 424.69 — 630.22 80.81 44.72 36.71 34.77 36.58 31.15 36.68 — — —
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 27.70 22.18 18.35 18.63 21.33 24.45 26.84 29.01 31.39 40.69 45.82 45.19 35.87 34.03 — — — — — — —
Cigna Group 9.34 10.40 12.05 10.20 10.40 9.08 9.12 9.28 11.13 9.03 9.24 7.58 8.59 8.38 — — — — — — —
CVS Health Corp. 11.67 14.75 20.01 9.97 10.06 10.43 9.43 7.87 7.61 6.65 5.89 5.98 6.19 7.83 — — — — — — —
Elevance Health Inc. 13.61 15.05 15.30 14.72 17.53 15.70 15.81 19.93 15.79 12.10 10.93 9.03 11.95 13.55 — — — — — — —
Humana Inc. 14.93 16.63 18.96 18.96 17.45 17.08 21.55 14.39 11.02 9.78 9.84 11.28 14.59 15.35 — — — — — — —
Intuitive Surgical Inc. 66.95 54.49 46.65 44.54 49.98 56.11 67.95 69.51 89.18 88.37 83.88 71.30 43.68 48.89 — — — — — — —
Medtronic PLC 19.55 20.48 25.40 27.20 38.83 37.44 49.88 42.55 35.86 26.29 21.01 23.52 22.21 21.26 — — — — — — —
UnitedHealth Group Inc. 15.41 15.89 18.75 19.96 19.69 18.77 19.63 19.05 16.12 14.12 12.35 11.85 13.80 14.40 — — — — — — —

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Data adjusted for splits and stock dividends.

2 Q1 2023 Calculation
Operating profit per share = (Operating income (loss)Q1 2023 + Operating income (loss)Q4 2022 + Operating income (loss)Q3 2022 + Operating income (loss)Q2 2022) ÷ No. shares of common stock outstanding
= (552,000,000 + 402,000,000 + 358,000,000 + 423,000,000) ÷ 1,437,698,101 = 1.21

3 Closing price as at the filing date of Boston Scientific Corp. Quarterly or Annual Report.

4 Q1 2023 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 51.94 ÷ 1.21 = 43.04

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Boston Scientific Corp. P/OP ratio decreased from Q3 2022 to Q4 2022 but then increased from Q4 2022 to Q1 2023 exceeding Q3 2022 level.

Price to Sales (P/S)

Boston Scientific Corp., historical P/S calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
No. shares of common stock outstanding1 1,437,698,101 1,434,780,104 1,432,311,282 1,431,614,313 1,429,571,199 1,426,724,712 1,424,992,477 1,423,852,648 1,420,910,855 1,417,165,707 1,431,921,459 1,430,674,668 1,399,350,122 1,396,195,349 1,393,823,592 1,392,973,426 1,390,652,506 1,385,961,926 1,383,800,781 1,382,924,777 1,379,810,502
Selected Financial Data (US$)
Net sales (in millions) 3,389 3,242 3,170 3,244 3,026 3,127 2,932 3,077 2,752 2,708 2,659 2,003 2,543 2,904 2,707 2,631 2,493 2,561 2,393 2,490 2,379
Sales per share2 9.07 8.84 8.77 8.61 8.51 8.33 8.05 7.86 7.12 6.99 7.06 7.10 7.71 7.69 7.46 7.23 7.15 7.09 0.00 0.00 0.00
Share price1, 3 51.94 47.18 41.53 41.23 42.03 43.71 42.50 44.70 43.04 38.75 35.21 37.73 35.89 39.91 40.59 42.86 36.73 39.86 35.38 33.61 29.48
Valuation Ratio
P/S ratio4 5.72 5.34 4.73 4.79 4.94 5.25 5.28 5.68 6.04 5.54 4.99 5.31 4.66 5.19 5.44 5.92 5.14 5.62 — — —
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 4.64 4.25 3.85 4.18 4.42 4.78 5.38 5.36 5.64 6.30 6.13 5.77 5.09 4.83 — — — — — — —
Cigna Group 0.42 0.49 0.55 0.48 0.48 0.42 0.42 0.42 0.55 0.46 0.50 0.41 0.45 0.44 — — — — — — —
CVS Health Corp. 0.27 0.36 0.40 0.43 0.44 0.47 0.45 0.39 0.40 0.35 0.32 0.32 0.30 0.37 — — — — — — —
Elevance Health Inc. 0.68 0.74 0.77 0.75 0.89 0.81 0.78 0.73 0.76 0.60 0.61 0.63 0.65 0.74 — — — — — — —
Humana Inc. 0.66 0.68 0.78 0.68 0.65 0.65 0.73 0.71 0.73 0.64 0.76 0.76 0.74 0.76 — — — — — — —
Intuitive Surgical Inc. 16.21 13.81 12.62 12.69 15.34 17.89 22.12 21.73 23.19 21.29 20.09 18.44 13.33 15.01 — — — — — — —
Medtronic PLC 3.79 3.72 4.54 4.54 5.74 5.57 5.71 5.43 5.11 4.36 4.34 4.82 4.72 4.36 — — — — — — —
UnitedHealth Group Inc. 1.37 1.40 1.62 1.66 1.61 1.58 1.55 1.47 1.49 1.24 1.18 1.17 1.12 1.18 — — — — — — —

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Data adjusted for splits and stock dividends.

2 Q1 2023 Calculation
Sales per share = (Net salesQ1 2023 + Net salesQ4 2022 + Net salesQ3 2022 + Net salesQ2 2022) ÷ No. shares of common stock outstanding
= (3,389,000,000 + 3,242,000,000 + 3,170,000,000 + 3,244,000,000) ÷ 1,437,698,101 = 9.07

3 Closing price as at the filing date of Boston Scientific Corp. Quarterly or Annual Report.

4 Q1 2023 Calculation
P/S ratio = Share price ÷ Sales per share
= 51.94 ÷ 9.07 = 5.72

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Boston Scientific Corp. P/S ratio increased from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.

Price to Book Value (P/BV)

Boston Scientific Corp., historical P/BV calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
No. shares of common stock outstanding1 1,437,698,101 1,434,780,104 1,432,311,282 1,431,614,313 1,429,571,199 1,426,724,712 1,424,992,477 1,423,852,648 1,420,910,855 1,417,165,707 1,431,921,459 1,430,674,668 1,399,350,122 1,396,195,349 1,393,823,592 1,392,973,426 1,390,652,506 1,385,961,926 1,383,800,781 1,382,924,777 1,379,810,502
Selected Financial Data (US$)
Stockholders’ equity (in millions) 17,850 17,573 17,640 17,251 16,735 16,622 16,461 15,942 15,719 15,326 15,564 15,616 13,804 13,877 9,699 9,425 9,233 8,726 8,289 7,744 7,030
Book value per share (BVPS)2 12.42 12.25 12.32 12.05 11.71 11.65 11.55 11.20 11.06 10.81 10.87 10.92 9.86 9.94 6.96 6.77 6.64 6.30 5.99 5.60 5.09
Share price1, 3 51.94 47.18 41.53 41.23 42.03 43.71 42.50 44.70 43.04 38.75 35.21 37.73 35.89 39.91 40.59 42.86 36.73 39.86 35.38 33.61 29.48
Valuation Ratio
P/BV ratio4 4.18 3.85 3.37 3.42 3.59 3.75 3.68 3.99 3.89 3.58 3.24 3.46 3.64 4.02 5.83 6.33 5.53 6.33 5.91 6.00 5.79
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 5.21 5.06 4.85 5.21 5.56 5.75 6.61 6.38 6.27 6.65 6.30 5.94 5.40 4.96 4.65 4.86 4.49 — — — —
Cigna Group 1.73 1.95 2.20 1.86 1.84 1.53 1.49 1.44 1.86 1.46 1.61 1.34 1.51 1.49 1.49 1.44 1.42 — — — —
CVS Health Corp. 1.26 1.61 1.80 1.77 1.79 1.83 1.71 1.47 1.51 1.33 1.24 1.24 1.21 1.47 1.47 1.23 1.25 — — — —
Elevance Health Inc. 2.90 3.19 3.24 3.08 3.55 3.07 2.88 2.67 2.78 2.19 2.10 2.06 2.23 2.42 2.13 2.40 2.15 — — — —
Humana Inc. 3.81 4.13 4.36 3.91 3.66 3.34 3.63 3.82 3.99 3.55 3.55 3.71 4.04 4.07 3.48 3.38 3.07 — — — —
Intuitive Surgical Inc. 9.29 7.78 6.71 6.29 7.48 8.59 10.64 10.35 10.40 9.53 9.35 9.19 7.22 8.13 8.43 8.49 8.68 — — — —
Medtronic PLC 2.23 2.24 2.75 2.77 3.52 3.26 3.14 3.02 2.84 2.48 2.60 2.94 2.87 2.66 2.48 2.62 2.59 — — — —
UnitedHealth Group Inc. 5.60 5.81 6.80 6.94 6.54 6.27 6.13 5.76 5.86 4.83 4.54 4.53 4.81 4.92 4.32 4.40 4.37 — — — —

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Data adjusted for splits and stock dividends.

2 Q1 2023 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= 17,850,000,000 ÷ 1,437,698,101 = 12.42

3 Closing price as at the filing date of Boston Scientific Corp. Quarterly or Annual Report.

4 Q1 2023 Calculation
P/BV ratio = Share price ÷ BVPS
= 51.94 ÷ 12.42 = 4.18

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Boston Scientific Corp. P/BV ratio increased from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.